257 related articles for article (PubMed ID: 18047854)
1. Nicotinic acid (niacin) receptor agonists: will they be useful therapeutic agents?
Kamanna VS; Kashyap ML
Am J Cardiol; 2007 Dec; 100(11 A):S53-61. PubMed ID: 18047854
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of action of niacin.
Kamanna VS; Kashyap ML
Am J Cardiol; 2008 Apr; 101(8A):20B-26B. PubMed ID: 18375237
[TBL] [Abstract][Full Text] [Related]
3. Future of GPR109A agonists in the treatment of dyslipidaemia.
Wanders D; Judd RL
Diabetes Obes Metab; 2011 Aug; 13(8):685-91. PubMed ID: 21418500
[TBL] [Abstract][Full Text] [Related]
4. Nicotinic acid: recent developments.
Kamanna VS; Vo A; Kashyap ML
Curr Opin Cardiol; 2008 Jul; 23(4):393-8. PubMed ID: 18520725
[TBL] [Abstract][Full Text] [Related]
5. Nicotinic acid receptor subtypes and their ligands.
Soudijn W; van Wijngaarden I; Ijzerman AP
Med Res Rev; 2007 May; 27(3):417-33. PubMed ID: 17238156
[TBL] [Abstract][Full Text] [Related]
6. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
[TBL] [Abstract][Full Text] [Related]
7. Flushing out the role of GPR109A (HM74A) in the clinical efficacy of nicotinic acid.
Pike NB
J Clin Invest; 2005 Dec; 115(12):3400-3. PubMed ID: 16322787
[TBL] [Abstract][Full Text] [Related]
8. Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs.
Le Bloc'h J; Leray V; Chetiveaux M; Freuchet B; Magot T; Krempf M; Nguyen P; Ouguerram K
J Pharmacol Exp Ther; 2010 Aug; 334(2):583-9. PubMed ID: 20442223
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in niacin and lipid metabolism.
Kamanna VS; Ganji SH; Kashyap ML
Curr Opin Lipidol; 2013 Jun; 24(3):239-45. PubMed ID: 23619367
[TBL] [Abstract][Full Text] [Related]
10. GPR109A (PUMA-G/HM74A) mediates nicotinic acid-induced flushing.
Benyó Z; Gille A; Kero J; Csiky M; Suchánková MC; Nüsing RM; Moers A; Pfeffer K; Offermanns S
J Clin Invest; 2005 Dec; 115(12):3634-40. PubMed ID: 16322797
[TBL] [Abstract][Full Text] [Related]
11. Niacin stimulates adiponectin secretion through the GPR109A receptor.
Plaisance EP; Lukasova M; Offermanns S; Zhang Y; Cao G; Judd RL
Am J Physiol Endocrinol Metab; 2009 Mar; 296(3):E549-58. PubMed ID: 19141678
[TBL] [Abstract][Full Text] [Related]
12. Niacin lipid efficacy is independent of both the niacin receptor GPR109A and free fatty acid suppression.
Lauring B; Taggart AK; Tata JR; Dunbar R; Caro L; Cheng K; Chin J; Colletti SL; Cote J; Khalilieh S; Liu J; Luo WL; Maclean AA; Peterson LB; Polis AB; Sirah W; Wu TJ; Liu X; Jin L; Wu K; Boatman PD; Semple G; Behan DP; Connolly DT; Lai E; Wagner JA; Wright SD; Cuffie C; Mitchel YB; Rader DJ; Paolini JF; Waters MG; Plump A
Sci Transl Med; 2012 Aug; 4(148):148ra115. PubMed ID: 22914621
[TBL] [Abstract][Full Text] [Related]
13. Modulation of HDL metabolism by the niacin receptor GPR109A in mouse hepatocytes.
Li X; Millar JS; Brownell N; Briand F; Rader DJ
Biochem Pharmacol; 2010 Nov; 80(9):1450-7. PubMed ID: 20655299
[TBL] [Abstract][Full Text] [Related]
14. The nicotinic acid receptor GPR109A (HM74A or PUMA-G) as a new therapeutic target.
Offermanns S
Trends Pharmacol Sci; 2006 Jul; 27(7):384-90. PubMed ID: 16766048
[TBL] [Abstract][Full Text] [Related]
15. Niacin mediates lipolysis in adipose tissue through its G-protein coupled receptor HM74A.
Zhang Y; Schmidt RJ; Foxworthy P; Emkey R; Oler JK; Large TH; Wang H; Su EW; Mosior MK; Eacho PI; Cao G
Biochem Biophys Res Commun; 2005 Aug; 334(2):729-32. PubMed ID: 16018973
[TBL] [Abstract][Full Text] [Related]
16. Niacin: an old drug rejuvenated.
Kamanna VS; Ganji SH; Kashyap ML
Curr Atheroscler Rep; 2009 Jan; 11(1):45-51. PubMed ID: 19080727
[TBL] [Abstract][Full Text] [Related]
17. Differential tissue and ligand-dependent signaling of GPR109A receptor: implications for anti-atherosclerotic therapeutic potential.
Gaidarov I; Chen X; Anthony T; Maciejewski-Lenoir D; Liaw C; Unett DJ
Cell Signal; 2013 Oct; 25(10):2003-16. PubMed ID: 23770183
[TBL] [Abstract][Full Text] [Related]
18. Triglyceride modulation by acifran analogs: activity towards the niacin high and low affinity G protein-coupled receptors HM74A and HM74.
Mahboubi K; Witman-Jones T; Adamus JE; Letsinger JT; Whitehouse D; Moorman AR; Sawicki D; Bergenhem N; Ross SA
Biochem Biophys Res Commun; 2006 Feb; 340(2):482-90. PubMed ID: 16389067
[TBL] [Abstract][Full Text] [Related]
19. PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect.
Tunaru S; Kero J; Schaub A; Wufka C; Blaukat A; Pfeffer K; Offermanns S
Nat Med; 2003 Mar; 9(3):352-5. PubMed ID: 12563315
[TBL] [Abstract][Full Text] [Related]
20. 1-Alkyl-benzotriazole-5-carboxylic acids are highly selective agonists of the human orphan G-protein-coupled receptor GPR109b.
Semple G; Skinner PJ; Cherrier MC; Webb PJ; Sage CR; Tamura SY; Chen R; Richman JG; Connolly DT
J Med Chem; 2006 Feb; 49(4):1227-30. PubMed ID: 16480258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
